Kornimate/medical-research-clean huggingface dataset:
the effect of situation puzzle games on nursing students' death anxiety and meaning in life

Conditions: Death Anxiety

Summary: goal of this interventional study the purpose of this research is to investigate the effects of a scenario-based puzzle educational game on death anxiety and meaning in life among nursing students. it aims to answer the following key questions: can the scenario-based puzzle educational game enhance nursing students' sense of meaning in life? can the scenario-based puzzle educational game reduce death anxiety in nursing students? what are nursing students' experiences and perceptions of this educational game? study design researchers will compare the intervention group (participating in the game) with a control group (receiving death education manuals) to evaluate the effectiveness of the game-based intervention. participants will: be recruited through campus posters be randomly assigned to either the intervention or control group and complete baseline questionnaires in the control group: receive death education manuals twice weekly for 3 weeks in the intervention group: participate in group sessions (5 students per group) to play the scenario-based puzzle game twice weekly for 3 weeks complete follow-up questionnaires and participate in qualitative interviews regarding their experiences with manual-based education or the game intervention after the 3-week intervention period


Eligibility criteria:
inclusion criteria: * third-year full-time undergraduate nursing students * completed clinical observation training but not yet entered clinical internship phase * aged ≥18 years * provide informed consent and voluntarily participate in the study exclusion criteria: * participated in similar death education interventions within the past 3 months * diagnosed with severe mental or psychological disorders * currently on a leave of absence (academic or personal)
perle (peroneus longus evaluation): a study evaluating the efficacy of injection of dysport in peroneus longus in equinus foot deformity in children with cerebral palsy

Conditions: Equinus Foot Deformity in Children With Cerebral Palsy

Summary: a recent publication (boulay et al. 2012) highlighted the role of the peroneus longus (pl) muscle in equinus foot deformity in children with hemiplegia. bont (dysport) injections into this muscle have not yet been described in the literature. based on the results of a previous study, the hypothesis is: this muscle may thus constitute a new therapeutic target for botulinum toxin injections in the early management of spastic equinus in children aged 2 years or older, before the onset of fixed neuro-orthopedic deformity and the midfoot break. the aim of this retrospective study is to describe in intramuscular bont (dysport) injections into pl based on the results obtained in a cohort of children (approximately 30 subjects) with cerebral palsy (hemiplegia or diplegia) and which have been treated in the service since 2007 until july 2012. the investigators results are based on clinical, radiological and video evaluations. for this study, data will be collected in medical folder of each children belonging to this cohort. all children (approximately 30 subjects) with cerebral palsy (hemiplegia or diplegia) which have been treated by bont (dysport) intramuscular injections into pl in the service between 2007 and july 2012 will be screened. subjects will be selected according to the following defined inclusion and exclusion criteria. data will be collected retrospectively (using a specific case report form designed for the study) in medical folder of each included subject for all visit of follow-up after bont (dysport) injection into pl (since the first bont (dysport) injection up to 2012). then, data will be entered in a database. after that, they will be analysed .


Eligibility criteria:
inclusion criteria: * children between 2 and 6 years of age with cerebral palsy treated by intramuscular injection of bont (dysport) into the pl (only) between 2007 and 2012. * at least one bont (dysport) injection performed into pl only * hemiplegic or diplegic subjects * dynamic equinus with hindfoot valgus with a documented premature onset activity of the peroneus longus which occurred earlier than the onset of gastrocnemius medialis (gm) activity, during terminal sw (i.e. emg background data available). * evaluation based on gross motor function classification system (gmfcs ≤ 2) performed for children aged to 6-12 years (i.e available in the subject's medical folder). * feet xrays data available before the first injection of bont (dysport) and after for each subject * pre- and post-bont (dysport) injection radiological data available in the subjects's medical folder exclusion criteria: * equinus deformity due to a triceps surae contracture and a limb length discrepancy over 1 cm. * other muscle than pl injected with bont (dysport) during the evaluation period (between the pre- ant post-bont (dysport) radiological evaluation)
effect of opioid-free analgesia and anesthesia on the quality of postoperative recovery and nausea vomit in patients receiving laparoscopic sleeve gastrectomy

Conditions: Opioid-Free Anesthesia; Laparoscopic Sleeve Gastrectomy; Postoperative Vomiting; Postoperative Recovery

Summary: the purpose of the intraoperative use of opioids is to reduce the amount of sedative medication and to ensure effective analgesia. but pain is an unpleasant sensory and emotional experience (a cognitive perception) that cannot occur with sufficient depth of anesthesia (even without opioids). so a more reasonable explanation for analgesia should be anti-nociception and the resulting inhibition of the response to surgical stress. since multiple mediators are involved in nociceptive pathways, antinociception can also be acquired through multiple mechanisms. however, there is no single ideal harm drug to replace opioids, which often requires two or more drugs to meet clinical needs. while regional block attenuates the stress response to surgery and sympathetic activation because of afferents to block nociceptive stimuli, and has an important role in the implementation of ofa. combined with the clinical characteristics of the lsg, investigators developed the transverse abdominis fascia block (transversus abdominis plane tap) in combination with esketamine (esketamine), dexmedetomidine (dexmedetomidine, dex) of opioid-free anesthesia (opioid free anesthesia, ofa) and the analgesic regimen (tedofa), reduce patient pain scores, nausea and vomiting after lsg based on perfect analgesia and adequate anti-sympathetic response, as well as the other complications, promote the accelerated postoperative recovery of patients undergoing lsg, and reduce the incidence and severity of postoperative chronic pain.


Eligibility criteria:
inclusion criteria: * patients undergoing elective laparoscopic sleeve gastrectomy * asaa i or grade; * volunteered in this trial and signed informed consent; ④ age 18-65 years; ⑤ bmi\> 30kg / m2. exclusion criteria: * chronic pain; * severe liver dysfunction (total bilirubin 2 mg dl-1); * severe renal dysfunction (glomerular filtration rate 60ml min-1 1.73m-2); * pregnancy or lactation; * preoperative heart rate \<50 beats / min, sick sinus syndrome, severe heart block; -dementia or significant neurological disorders (such as stroke, epilepsy, intracranial tumors, pd, etc.); * history of alcohol or drug abuse
the impact of opioids in coronary heart disease

Conditions: Coronary Heart Disease

Summary: in this study, the risk of opioid medications on coronary heart disease in adults is investigated. patients with the necessity of a coronary angiography and control patients with a non-cardiac disease of the same hospital are inquired with a standardized questionnaire about demographic and clinical risk factors for heart attack. an impact of opioid medications on coronary heart disease is hypothesised (miop). in addition, all patients with coronary angiography should be consulted twice (after 3 and 6 months) to find out how many of these patients have developed a refractory angina pectoris (traps).


Eligibility criteria:
inclusion criteria: * 40 years or older * written informed consent exclusion criteria: * currently cancer * cognitive limitations
the effect of vibration therapy over neck myofascial trigger points

Conditions: Myofascial Trigger Point Pain; Neck Pain

Summary: the aim of this study was to investigate the efficacy of a self-administered vibration therapy treatment on neck pain, disability and pressure pain thresholds in patients with non-specific neck pain and myofascial trigger points (mtrps). the investigators hypothesized that patients receiving vibration therapy would report less perceived neck pain, disability and present higher ppts after receiving vibration therapy when compared to a control no-treatment group.

myofascial trigger points (mtrps) are a common source of (regional) pain in patients presenting with musculoskeletal pain. mechanical vibration has been suggested as a treatment for pain relief. in this study, the effects of vibration therapy on people with non-specific neck pain and mtrps were investigated. seventeen chronic non-specific neck pain patients were randomly assigned to a treatment (vibration group, n = 9) or control group (n = 8). vibration group received 10 self-administered sessions of vibration therapy (45-50 hz for 15 minutes with the subject laying in supine). perceived neck pain and disability and pressure pain thresholds over mtrps of the upper trapezius and levator scapulae bilateraly were measured at baseline and after the first, five and 10 treatment sessions.

Eligibility criteria:
inclusion criteria: * a score of ≥ 5/50 in neck disability index * active or latent myofascial trigger points in upper trapezius or levator scapulae muscles exclusion criteria: * previous cervical spine surgery * cervical radiculopathy * severe systemic disease * fibromyalgia * other widespread musculoskeletal pain syndromes * patients being treated with medication or physiotherapy within the last 4 weeks

Keywords: vibration pressure pain threshold trigger points neck pain
anlotinib for hepatocellular carcinoma

Conditions: Liver Neoplasms

Summary: the purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced liver cancer in the real world, and to summarize the treatment experience of a wide range of people.


Eligibility criteria:
inclusion criteria: 1. age: ≥ 18 years old, male or female; 2. patients with advanced liver cancer were diagnosed; 3. patients assessed by doctors to benefit from single or combined treatment of arotinib; 4. patients volunteered to join the project. exclusion criteria: none
understanding and preventing cortical mechanisms of chemotherapy-induced peripheral neuropathy

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: cohort 1: to track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (cipn). cohort 2: to track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (cipn) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clbci) to see if can help to prevent pain due to cipn.

primary objectives: objective 1 (primary objective): to examine preliminary baseline and serial electrophysiological markers associated with the onset and development of cipn by tracking brain activity and cipn symptoms throughout chemotherapy treatment. secondary objectives: objective 2 (secondary objective): to preliminarily evaluate whether a clbci program can regulate changes in eeg that are associated with cipn while participants are undergoing chemotherapy. exploratory objective: explore whether there are associations between change in brain function and subjective report of cipn.

Eligibility criteria:
inclusion criteria: objective 1 inclusion criteria 1. participants must have the ability to understand and read english, sign a written informed consent, and be willing to follow protocol requirements. 2. ecog performance status of 0-2; 3. willing to come to md anderson for the imaging sessions. 4. are 18 years of age or above. 5. have a diagnosis of breast cancer. 6. will receive chemotherapy including doxorubicin, cyclophosphamide, docetaxel, or paclitaxel; objective 2 inclusion criteria: 1) inclusion criteria: identical to objective 1 and are willing to participate in the therapy sessions at their homes. exclusion criteria objective 1 exclusion criteria: 1. participants who are taking any antipsychotic medications. 2. with active cns disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy. 3. have ever been diagnosed with bipolar disorder or schizophrenia. 4. known, previously diagnosed peripheral neuropathy from causes other than chemotherapy; and 5. a history of head injury or who have known seizure activity, or with a prior history of chemotherapy. 6. patients who will be administered ddac-\>t. objective 2 exclusion criteria 1) same exclusion criteria as in objective1. medication usage will be tracked for patients in all groups. once prescribed, participants must remain on a stable course of medications throughout the course of chemotherapy.
deconstructing post stroke hemiparesis

Conditions: Stroke

Summary: tracts (deconstructing post stroke hemiparesis for precision neurorehabilitation) is a single timepoint study that aims to deconstruct post-stroke deficits of the upper extremity into distinct components and relate these components to brain anatomy and physiology.

veterans will be recruited through the providence veterans affairs medical center and will have research visits at the providence va center for neurorestoration and neurotechnology (cfnn, centerforneuro.org). the research visits will span two to three days. the study will involve motor outcome measures, magnetic resonance imaging of the brain, and transcranial magnetic stimulation. the goal of this study is to associate post-stroke deficits of the upper extremity with brain anatomy and physiology.

Eligibility criteria:
inclusion criteria: * diagnosis of a unilateral ischemic stroke occurring \>6 months prior as documented in medical chart * upper extremity motor impairment as measured by fugl-meyer upper extremity assessment ≤60 * ability to follow simple instructions in english exclusion criteria: * greater than moderate difficulty using the arm and hand pre-dating the stroke as assessed by the questions adapted from the quickdash outcome measure score on any question \>= 3, which measures physical function and symptoms in people with difficulty using the arm and hand. * visual or auditory disorders resulting in the inability to see or hear, respectively, the stimuli presented as part of research sessions * inability to maintain a seated position for at least one hour * standard mri exclusion (e.g., significant claustrophobia or inability to tolerate loud noises, cardiac pacemaker (unless mri-safe), implanted device (deep brain stimulation) or metal in the brain, cervical spinal cord, or upper thoracic spinal cord) * standard (single-pulse) tms exclusion which include (in addition to those listed for mri) pregnancy/lactation/planning to become pregnant during the study, seizure disorder, and primary or secondary cns tumors
evaluation of the accuracy of a computer vision-based tool for assessment of total body fat percentage

Conditions: Obesity

Summary: this research study is designed to validate the precision and accuracy of body measurement and composition results from a novel 2d imaging device that operates through a smart-phone application. measurement references will be obtained through dual energy x-ray absorptiometry, air displacement plethysmography, bioelectrical impedance analysis, manual anthropometry, and previously validated 3d optical scanners.

participation in this study will require a single 3-hour visit to complete. each person will be asked to arrive at pbrc wearing easily removable gym-style clothing. upon checking in, they will first complete the informed consent process, then have their vital signs checked, and then women of child-bearing potential will also have a urine sample taken. outpatient clinic procedures will be followed by a series of body size and composition assessments that will require an outfit of minimal clothing. clean spandex shorts, sports bras, and lycra caps will be provided. * anthropometric measurements including hip, waist, arms, and thighs circumferences will be collected by a trained observer using a calibrated tape measure. * body shape will be measured digitally using 2d and 3d optical devices that optimize light patterns to calculate depth. * bioelectrical impedance analysis measures the amount of fat and lean mass in the body using electrodes positioned close to the feet and hands. * whole body dual-energy x-ray absorptiometry measures the amount of bone, muscle, and fat mass in the body using low energy x-rays. * air displacement plethysmography estimates whole body volume, fat mass, and fat-free mass of the body using variations in air pressure

Eligibility criteria:
inclusion criteria: * being either male or female * being from 21 to 80 years of age * having a body weight of less than 440 pounds * being willing to comply with the study procedures exclusion criteria: * being pregnant or attempting to become pregnant * having medical implants such as a pacemaker or metal joint replacements * having undergone any previous body altering procedures such as breast augmentation or amputation * having a body weight greater than 440 pounds
intratracheal dexmedetomidine versus lidocaine in eye surgery

Conditions: Postoperative Complications

Summary: cough during emergence from general anesthesia is considered a critical event as it may lead to surgical bleeding laryngospasm hemodynamic instability and could be life-threatening in patients who are at risk of complications related to increases in intracranial or intraocular pressure. lidocaine administration has been widely used for reducing cough during extubation due to its simplicity and lack of serious adverse effects; there are two major routes for lidocaine administration systemic intravenous injection and local direct application on the laryngeal inlets such as spraying lidocaine on the supraglottic and subglottic regions or applying lidocaine jelly or sprayed. dexmedetomidine is a potent alpha 2 selective adrenoceptor agonist and the most characteristic features include sympatholytic sedation analgesia and lack of respiratory depression. the aim of this study is to compare the effect of intratracheal dexmedetomidine and lidocaine on cough reflex in cataract surgery.

the patients were randomly allocated into three groups each containing (40) patient. group d received (0.5 μg/kg) of dexmedetomidine diluted and completed to 5 ml saline, group l received (5ml) 2% of lidocaine and group c received 5ml saline. the drugs were sprayed down the intratracheal tube of patients. the following variables: hemodynamic parameters hr, map, and sao2 values in different times, preoperative iop, cough, steward recovery score (srs), detection of awareness and extubation time, the incidence of complications due to increasing iop and surgeon satisfaction

Eligibility criteria:
inclusion criteria: * adult patients aged from 18 to 60 years old * asa i or ii class * undergo elective intraocular surgery * under general anesthesia. exclusion criteria: * renal impairment * cardiorespiratory abnormalities * bronchial asthma copd * restrictive lung diseases * liver failure * allergy to drugs will be used * patient refuse * pregnancy-lactation * significant obesity

Keywords: intratracheal dexmedetomidine eye-surgery lidocaine
efficacy of changing to duotrav® (travoprost 0.004%/timolol 0.5% bak-free fixed combination) from prior therapy

Conditions: Glaucoma

Summary: the purpose of this study is to assess efficacy and tolerability of changing to duotrav® (travoprost 0.004%/timolol 0.5% bak-free) from prior xalacom® or ganfort® fixed combination pharmacotherapy in patients with open-angle glaucoma or ocular hypertension with uncontrolled intraocular pressure (iop).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension, open-angle glaucoma, or pigment dispersion glaucoma in both eyes. * on a stable iop-lowering regimen of prostaglandin fixed combination (either xalacom or ganfort) within 4 weeks prior to the screening visit. * iop between 19 and 35 mmhg at any time of day in at least 1 eye. * best corrected visual acuity (bcva) of 6/60 (20/200 snellen; 1.0 logmar) or better in each eye. * willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study. * other protocol-defined inclusion criteria may apply. exclusion criteria: * known medical history of allergy, hypersensitivity, or poor tolerance to any component of duotrav® deemed clinically significant in the opinion of the principal investigator. * corneal dystrophies in either eye. * risk of visual field or va worsening as a consequence of participation in the study, in the investigator's best judgment. * any disease or condition that would preclude the safe administration of a topical beta-blocker, present a special risk to the subject, or interfere with optimal participation in the study. * women who are pregnant or lactating. * participation in any other investigational study within 30 days prior to the screening visit. * other protocol-defined exclusion criteria may apply.

Keywords: open-angle glaucoma ocular hypertension pigment dispersion glaucoma